These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 467002)

  • 1. Indirect evidence for a feedback loop mechanism between two central dopaminergic pathways: preliminary results.
    Yehuda S
    Commun Psychopharmacol; 1979; 3(2):115-9. PubMed ID: 467002
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 3. D-Amphetamine-induced inhibition of central dopaminergic neurons: direct effect or mediated by a striatonigral feedback pathway?
    Bunney BS; Aghajanian GK
    Adv Biochem Psychopharmacol; 1977; 16():577-82. PubMed ID: 883560
    [No Abstract]   [Full Text] [Related]  

  • 4. [Participation of rat cerebral dopaminergic structures in the process of reproducing conditioned passive avoidance reactions].
    Spiridonov VK
    Neirofiziologiia; 1976; 8(2):209-11. PubMed ID: 1272468
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopaminergic involvement in hypothalamic function: extrahypothalamic and hypothalamic control. A neuroanatomical analysis.
    Fuxe K; Goldstein M; Hökfelt T; Jonsson G; Lidbrink P
    Adv Neurol; 1974; 5():405-19. PubMed ID: 4374065
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo electrochemical and behavioral evidence for specific neural substrates modulated differentially by enkephalin in rat stimulant stereotypy and locomotion.
    Broderick PA; Gardner EL; van Praag HM
    Biol Psychiatry; 1984 Jan; 19(1):45-54. PubMed ID: 6538442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 10. The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions.
    Crossman AR; Sambrook MA
    Brain Res; 1978 Dec; 159(1):211-3. PubMed ID: 569529
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the striato-nigral pathway responsible for 'feed-back' control of dopamine release [proceedings]?
    Arbuthnott GW; Garcia-Munoz M; Nicolaou NM; Tulloch IF; Wright AK
    Br J Pharmacol; 1976 Oct; 58(2):272P. PubMed ID: 974393
    [No Abstract]   [Full Text] [Related]  

  • 12. [Morphine-like peptides and dopaminergic pathways].
    Destee A
    LARC Med; 1981 Dec; 1(3):53-4, 57-8. PubMed ID: 6298510
    [No Abstract]   [Full Text] [Related]  

  • 13. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 15. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J
    Adv Neurol; 1990; 53():425-9. PubMed ID: 2122648
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mesolimbic system of the brain and its participation in the action of psychotropic substances (a review of the literature)].
    Arushanian EB
    Farmakol Toksikol; 1977; 40(5):623-30. PubMed ID: 336388
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

  • 18. Amphetamine-induced rotation reveals post 6-OHDA lesion neurochemical reorganization.
    Lynch MR; Carey RJ
    Behav Brain Res; 1989 Feb; 32(1):69-74. PubMed ID: 2495013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
    Goldstein M; Lew JY; Asano T; Ueta K
    Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of injecting 6-hydroxydopamine into areas of the nigro-striatal (A9) and mesolimbic (A10) dopaminergic systems on the elaboration of a conditioned feeding reflex in the rat].
    Zhukova EM; Spiridonov VK; Loskutova LV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1987; 37(1):88-94. PubMed ID: 3107237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.